Advaxis announced the presentation of ADXS-NEO data in a poster discussion entitled “Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research Annual Meeting underway in Atlanta. The discussion will be held on Sunday, March 31. “Advaxis’ ADXS-NEO is a novel, personalized vaccine encoding mutations specific to an individual patient’s tumor designed to induce anti-cancer immunity. Four patients have been evaluated across two dose levels thus far in this ongoing clinical trial. While dose level 1 was determined to be above the MTD, dose level -1a has been safe and well tolerated in two patients treated to date, with primarily Grade 1 and Grade 2 chills, fever and tachycardia. Substantial immunological activity was observed across both dose levels, including rapid neoantigen-specific CD8+ T cell generation, which is essential for potential clinical benefit. We look forward to the planned combination therapy arm with checkpoint inhibitors,” said J. Randolph Hecht, M.D., Professor of Clinical Medicine, David Geffen School of Medicine at UCLA and Director of the UCLA Gastrointestinal Oncology Program.
https://thefly.com/landingPageNews.php?id=2886363
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.